The new China dynamic, Trump 2.0, markets and more: See you next week at JPM
When we started putting together this year’s JPM agenda, we had three major focus areas: The transition to Trump 2.0; the on-again, off-again market recovery, and the evolving US-China dynamic.
These will be crucial forces affecting where biotech goes in 2025, and our goal is to give you — our reader and our audience in San Francisco — a roadmap for understanding them.
Last year, the China narrative was about Biosecure. This year’s China story is going to be about the explosion of high-quality, fast-follow assets that are being picked up by richly-funded startup consolidators and by pharma companies hunting for better deals. It’s a trend that has the potential to upend the venture capital investment thesis and how we value innovation, and we’ll talk about that with Sanofi’s head of R&D Houman Ashrafian and ARCH venture capital legend Bob Nelsen.
We’ll also talk about the macro market forces. Last year was better than 2023, but as our readers know from yesterday’s piece from Kyle LaHucik, the red-light, green-light biotech recovery has money pouring into new companies, but far fewer dollars coming out through IPOs and deals. We’ll have great conversations with Centerview’s Eric Tokat, our blue-ribbon investor panel with Founding Editor John Carroll; a recently IPO’d biotech, and others.
And then there’s Trump… The last eight weeks are proof that the next four years are going to be a volatile ride. We’ll give you a roadmap and a reality check, with former FDA Commissioner Scott Gottlieb, outgoing Medicare chief Meena Seshamani, PhMRA’s Stephen Ubl, and many others.
Our full agenda is stacked, and if you’ll be in San Francisco and don’t have a ticket to join us yet, you can get 10% off by using the discount code JPM25_10.
See you there, and come say hello at our event and around town! (If you’re not traveling to JPM, you can also join us virtually.)
— Drew
